Evicenter
Rinvoq (upadacitinib) in Rheumatoid arthritis
Manufacturer
AbbVie Inc.
Prescribing information
Rinvoq (opens in a new tab)
Questions
42
Last updated

All questions

Safety: Rinvoq (upadacitinib) in rheumatoid arthritis

8 questions · 5 sources

Monitoring

When should RINVOQ be delayed or interrupted for lab results or infections?

What lab monitoring does RINVOQ require?

“Neutropenia Treatment with RINVOQ was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000 cells/mm3). Treatment with RINVOQ is not recommended in patients with an ANC <1000 cells/mm3. Evaluate neutrophil counts at baseline and thereafter according to routine patient management. Lymphopenia Absolute lymphocyte counts (ALC) <500 cells/mm3 were reported in RINVOQ-treated patients. Treatment with RINVOQ is not recommended in patients with an ALC <500 cells/mm3. Evaluate at baseline and thereafter according to routine patient management. Anemia Decreases in hemoglobin levels to <8 g/dL were reported in RINVOQ-treated patients. Treatment should not be initiated or should be interrupted in patients with hemoglobin levels <8 g/dL. Evaluate at baseline and thereafter according to routine patient management. Lipids Treatment with RINVOQ was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Manage patients according to clinical guidelines for the management of hyperlipidemia. Evaluate patients 12 weeks after initiation of treatment and thereafter according to the clinical guidelines for hyperlipidemia. Liver enzyme elevations Treatment with RINVOQ was associated with increased incidence of liver enzyme elevation compared to placebo. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are observed during routine patient management and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.” (opens the source at this quote in a new tab)

Safety evidence

What are RINVOQ long-term safety rates in rheumatoid arthritis (infections, cancer, heart events, clots)?

Note: The long-term table prints "(-4.2 yrs. median)" for the August 2025 data cut; the rheumatoid arthritis overview page states ~4.2 years median for the same cut.

Infection precautions

Does RINVOQ require TB testing before and during treatment?

Safety

Does RINVOQ raise the risk of infections, death, cancer, heart events, or blood clots (boxed warning)?

“Serious Infections: RINVOQ-treated patients are at increased risk of serious bacterial (including tuberculosis [TB]), fungal, viral, and opportunistic infections leading to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids. Mortality: A higher rate of all-cause mortality, including sudden cardiovascular (CV) death, was observed with a Janus kinase inhibitor (JAKi) in a study comparing another JAKi with tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients ≥50 years with ≥1 CV risk factor. Malignancies: Malignancies have occurred in RINVOQ-treated patients. A higher rate of lymphomas and lung cancer (in current or past smokers) was observed with another JAKi when compared with TNF blockers in RA patients. Major Adverse Cardiovascular Events: A higher rate of CV death, myocardial infarction, and stroke was observed with a JAKi in a study comparing another JAKi with TNF blockers in RA patients ≥50 years with ≥1 CV risk factor. History of smoking increases risk. Thromboses: Deep venous thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ. A higher rate of thrombosis was observed with another JAKi when compared with TNF blockers in RA patients.” (opens the source at this quote in a new tab)

Note: The higher rates of death, lymphoma and lung cancer, major cardiovascular events, and thrombosis in the boxed warning were observed with another JAK inhibitor compared with TNF blockers.

What are the most common RINVOQ side effects in rheumatoid arthritis?

What are the contraindications to RINVOQ?

What should patients do if they take too much RINVOQ?

Note: The RINVOQ prescribing information has no Overdosage section; this instruction is from the Medication Guide printed with it.